ClinicalTrials.gg
CompletedNCT04335279SPIN-CHATUpdated Feb 1, 2023Results posted

Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program

An interventional study of SPIN-CHAT Program in Scleroderma, Scleroderma, Systemic and Systemic Sclerosis, sponsored by Lady Davis Institute. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-01.

Sponsored by Lady Davis Institute · Not applicable, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 34 studies in Scleroderma, Diffuse with a site in Canada — 5 open to participants now, 8 under way, 2 of them phase 3. Scleroderma, Diffuse · Canada.

Enrollment
10th of 32
172 · median 82
Started
2020
the only one that year
No phase
11 of 34
2 open now
Registered
21st of 34
by date
Lead sponsor
9 of 34
Lady Davis Institute

Among the 34 studies in Scleroderma, Diffuse with a site in Canada, this one is the 10th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2020, is one of 11 with no phase, and was the 21st registered.

Scleroderma, Diffuse

310 studies on the registry are indexed under Scleroderma, Diffuse; 76 are open to participants now.

Browse Scleroderma, Diffuse studies →

Open to participants now

5 of the 34 studies in Scleroderma, Diffuse with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 55 Scleroderma, Diffuse studies recruiting now, 28 (51%) set no upper age limit and 20 (36%) stop at 75 or younger; 10 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Scleroderma, Diffuse with a site in Canada, or all of them as a file.
02

Study summary

Contagious disease outbreaks, such as the coronavirus disease 2019 (COVID-19) outbreak, and associated restrictions to prevent spread can lead to negative psychological outcomes, including loneliness, depression, and anxiety, particularly in vulnerable populations at risk due to existing medical conditions. To date, no randomized controlled trials have tested interventions to reduce mental health consequences of contagious disease outbreaks.

Systemic sclerosis (SSc; scleroderma) is a rare, chronic, autoimmune disease characterized by vasculopathy and excessive collagen production. Systemic Sclerosis can affect multiple organ systems, including the skin, lungs, gastrointestinal tract, and heart. Many people with scleroderma are at risk of serious complications from COVID-19 if infected due to lung involvement (> 40% have interstitial lung disease) and common use of immunosuppressant drugs.

The objective of The Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Trial is to evaluate a videoconference-based intervention designed to improve symptoms of anxiety and other mental health outcomes among individuals with systemic sclerosis at risk of poor mental health during the COVID-19 pandemic. The trial is a pragmatic randomized controlled trial that will be conducted using an existing cohort of systemic sclerosis patients. We will use a partially nested design to reflect dependence between individuals in training groups but not in the waitlist control. The SPIN-CHAT Program includes activity engagement, education on strategies to support mental health, and mutual participant support.

Read the detailed description

Background: Social distancing and movement restrictions during contagious disease outbreaks are necessary to reduce spread but can lead to negative social and psychological outcomes, including loneliness, depression, and anxiety, particularly in vulnerable populations. An online survey that used snowball sampling techniques and collected data from 1210 respondents from 194 cities in China in January-February 2020 found that over 50% rated the psychological impact of the coronavirus disease 2019 (COVID-19) outbreak as moderate or severe. Symptoms of anxiety were rated as the most common psychological problem. Self-reported poor physical health status and the presence of a chronic illness were associated with symptoms of depression and anxiety.

Systemic sclerosis (SSc; scleroderma) is a rare, chronic, autoimmune disease characterized by vasculopathy and excessive collagen production. Onset typically occurs between the ages of 30 and 50 years, and approximately 80% of people with SSc are women. SSc can affect multiple organ systems, including the skin, lungs, gastrointestinal tract, and heart. Disease presentation is extremely heterogeneous, and the course of the disease is highly unpredictable. People with SSc commonly experience hand function and mobility limitations, pain, fatigue, sleep problems, pruritus, symptoms of depression, and body image distress from disfiguring aspects (e.g., skin tightening, pigment changes, hand contractures, telangiectasias). Many people with SSc are at risk of serious complications from COVID-19 if infected due to lung involvement (> 40% have interstitial lung disease) and common use of immunosuppressant drugs.

The Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program is a group videoconference-based intervention designed to improve symptoms of anxiety and other mental health outcomes among individuals with SSc at risk of poor mental health during the COVID-19 pandemic. The primary objective of the SPIN-CHAT Trial is to evaluate the effect of the program compared to waitlist control on patient reported symptoms of anxiety as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0 scores.

Recruitment and Enrolment: SPIN is a collaboration of SSc researchers, health care providers, people living with SSc, and patient organizations from Canada, the United States, Europe, Mexico and Australia that has assembled a large multinational patient cohort to collect longitudinal data on patient-reported outcomes in SSc and as a framework for embedding RCTs of e-health interventions. SPIN Cohort participants complete online assessments upon enrolment and at 3-month intervals. To date, over 2000 SSc patients from 47 centres have been enrolled in SPIN's web-based cohort (currently approximately 1800 active participants).

SPIN Cohort participants will be invited by email and by popups to enrol in the SPIN-COVID-19 Cohort, a sub-cohort of the SPIN Cohort. Additionally, recruitment announcements for the SPIN-COVID-19 Cohort will be posted on SPIN's social media and distributed through our patient organization partners. All SPIN-COVID-19 Cohort participants will be invited to complete measures at baseline and every two weeks for the duration of the COVID-19 pandemic. They will receive email reminders to complete bi-weekly follow-up assessments.

Participants in the SPIN-COVID-19 Cohort eligible for the SPIN-CHAT Trial will be provided with a brief description of the trial in the SPIN-COVID-19 Qualtrics platform and will be asked if they would be interested in participating in the trial. Those who express interest will be provided with an online version of the trial consent form, which they can also download, and will be given the options of (1) consenting to participate; (2) declining participation; or (3) requesting that a member of SPIN's research team call them to answer questions they have about participating in the trial before consenting.

Methods: The SPIN-CHAT Trial is a pragmatic, two-arm partially nested RCT (PN-RCT) that will be conducted using the SPIN-COVID-19 Cohort. Pragmatic RCTs are conducted to replicate real-world delivery of interventions as much as possible and support decisions on whether interventions should be provided in practice. The trial will be a PN-RCT because participants randomised to the intervention arm will be clustered into intervention groups, and members of each intervention group will interact during videoconference sessions; participants randomly assigned to the waitlist control will not be clustered and will only complete trial measures.

Random Selection and Allocation: SPIN-COVID-19 Cohort participants who provide consent for participation will be entered into different pools based on their availabilities and taking into consideration time zone differences. Once there are enough participants to complete an intervention group and assign an equal number of participants to waitlist control, SPIN personnel will provide the external service with an anonymised list of participants (only identification numbers will be provided) who could participate in an intervention group based on language and day and time availabilities. For each intervention group and waitlist control pairing, the service will randomly select 16 participants from the pool of enroled participants available based on language, day, and time and will randomly allocate 8 to the intervention group and 8 to the waitlist group using block randomization.This process will be repeated until trial enrolment is complete. One intervention and waitlist control pairing will include 18 participants (9 intervention, 9 waitlist) to accommodate the total number that we anticipate randomizing.

Intervention and Comparator: Mental health outcomes, including anxiety, among people in quarantine are associated with modifiable factors such as degree of isolation, boredom, and ability to manage worry and anxiety. In addition to psychological strategies, including worry reduction and meditative exercises, exercise has been shown to reduce anxiety. Among older adults, where isolation is a common challenge, activity and social engagement are commonly used to address loneliness and feelings of isolation. Recommendations for the World Health Organization and major national public health organizations for managing mental health during COVID-19 emphasize setting and following a routine, managing information sources and quantity, staying connected with others, and finding a way to be physically active.

The SPIN-CHAT Program is a brief group videoconference intervention that was developed based on best-practice principles for managing anxiety and worry, recommendations for maintaining mental health during COVID-19, and input from the SPIN COVID-19 Patient Advisory Team. Educational segments in each session will be delivered by a research team member with experience and training related to the topic. Leisure activities that will be done at the start of each session will include games (e.g., Pictionary, charades), creative activities (e.g., roll-a-story), cultural activities (e.g., virtual museum tours), social activities (e.g., share your favourite recipe). In the healthy information management and social connection segment, strategies will be provided and discussion will be facilitated on how to stay informed via accurate information sources while avoiding sensationalist and other non-helpful information. Information on using simple (e.g., phone) or more advanced technology (e.g., group videoconferencing) to stay connected will be discussed, along with strategies for connecting regularly with others. The managing worry segments will include an overview of worry, including what it is, the difference between helpful and harmful anxiety or worry, how to identify triggers of worry, and strategies to manage worry, including identifying different types of worrying, using worry journals, worry postponement, and worry time. Exercises will be done with the group to illustrate techniques. In the relaxation segments, an introduction to the purpose of relaxation techniques will be presented, and participants will be guided through brief breathing, mindfulness, and visualization exercises.

The physical activity segments will include an overview of the physical and psychosocial benefits of physical activity for maintenance of health for chronic disease management, including mental health during the COVID-19 pandemic; movement guidelines to ensure safety; and how to monitor daily physical activity. Participants will be guided through movement options for the home-based setting, including warm-ups, aerobic, and strength activities. Behaviour change techniques to foster building the habit of moving more at home will be taught, including goal-setting, scheduling, addressing barriers, and building social support.

Activity engagement sessions will be guided by the leisure education content model. Sessions will involve interactive group discussion about the benefits of leisure engagement for persons with SSc, addressing physical, social, emotional, intellectual and spiritual realms of health and wellbeing. Sessions will explore barriers to leisure for persons with SSc and includes tips for finding leisure resources within the participants' own homes, both in-person and online.

Sample Size: Effects of short anxiety-focused interventions in post-disaster settings are between 0.40 and 0.80 standardized mean difference (SMD). This is larger than estimated minimally important difference for the PROMIS Anxiety 4a v1.0 score (SMD = 0.23 to 0.34 SMD). For an assumed effect size of SMD = 0.50, a two-tailed test with alpha = 0.05, and an intra-class correlation coefficient (ICC) of 0.05, N=146 provides 80% power or greater for our primary outcome, PROMIS Anxiety 4a v1.0; assuming 10% dropout, we will recruit 162 participants (81 in 10 SPIN-CHAT groups; 81 waitlist). We believe that this is a conservative power and sample size estimate. First, in cluster RCTs, ICC values for individual patient outcomes are typically lower than our 0.05 estimate. If the true ICC is lower than our 0.05 estimate, this will result in greater power than estimated. Second, there has been no loss to follow-up in the feasibility trial or initial waves of our full-scale trial of the videoconference-based SPIN support group leader program, which has a similar design. Thus, we believe that a 10% loss to follow-up may be conservative.

Data Analysis: Analyses will be conducted by a statistician blind to trial arm allocation. For the primary outcome analysis, we will use an intent-to-treat analysis that compares all patients randomly assigned to the SPIN-CHAT Program to all patients assigned to the waitlist control. The intervention effect at 4 weeks will be estimated using a linear mixed model, adjusted for baseline PROMIS Anxiety 4a v1.0 scores. The model will include a random effect to account for clustering of participants in the training groups, but not for participants in the waitlist control arm, because there is no clustering in the control arm. We will investigate the effects of missing data using multiple imputation. As a secondary analysis, we will additionally adjust for age, sex, baseline loneliness, baseline boredom, and baseline physical activity. Analyses of secondary outcomes will similarly be done (1) controlling for baseline scores only and (2) controlling for baseline scores, age, sex, and other key baseline measures. Statistical significance for all analyses will be determined based on two-sided α = 0.05. In addition, we will use complier-average causal effect analysis to estimate effects among patients who use the intervention compared to similar patients in the waitlist arm of the trial.

03

Conditions studied

  • Scleroderma
  • Scleroderma, Systemic
  • Systemic Sclerosis

Keywords

  • Scleroderma
  • Systemic Sclerosis
  • COVID-19
  • E-health
  • Anxiety
  • Mental health
  • Trial
  • Coronavirus
  • RCT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Classified as having SSc by a physician
  • PROMIS Anxiety 4a v1.0 T-score greater than or equal to 55
  • Have regular, reliable internet access
  • Be fluent in English or French

Exclusion criteria

Exclusion Criteria:

  • Receiving counseling or therapy currently
  • Having a positive test for the COVID-19 virus
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    SPIN-CHAT: Videoconference Intervention

    Participants in the SPIN-CHAT videoconference intervention group will receive a brief group videoconference intervention aimed at the management of worry and anxiety 3 times per week for 4 weeks during the COVID-19 crisis. Each group will include 8 participants and sessions will be approximately 60- to 90-minutes each. Each intervention group will be moderated by a member of the research team or by leaders who have been trained in our SPIN support group leader training program.

    Other: SPIN-CHAT Program

  • No intervention
    Wait-list Control

    Participants in the wait-list control group will not receive the training program and will have no access to the resources indicated above for the duration of the trial. Wait-list controls will be given access to the program post-trial.

Interventions

  • OtherSPIN-CHAT Program

    Each session will include 3 segments: (1) engagement via therapeutic recreation activities (20-30 minutes); (2) education on information management and anxiety management through psychological and other strategies (20-30 minutes); and (3) open discussion and social support (20-30 minutes). Educational segment topics will include (1) healthy information management and social connection (session 1); (2) managing worry (sessions 2, 6, 10); (3) relaxation strategies (sessions 3; 7, 11); (4) adapted home exercise (sessions 4, 8, 12); and (5) activity engagement at home (sessions 5 and 9). All educational segments will be supported by resource materials available to participants via an online SPIN-CHAT resource link. Supervision and support of group moderators will be provided by a trained social worker. Educational segments in each session will be delivered by a research team member with experience and training related to the topic.

06

What researchers measure

Primary outcomes

  1. Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0

    The PROMIS Anxiety 4a v1.0 is a 4 item scale that asks participants, in the past 7 days, how often: (1) "I felt fearful"; (2) "I found it hard to focus on anything other than my anxiety"; (3) "My worries overwhelmed me"; and (4) "I felt uneasy". Items are scored on a 5-point scale (range 1-5), and response options include "never", "rarely", "sometimes", "often", and "always". Raw scores are converted into T scores standardised in the US adult general population (mean=50, standard deviation=10). Higher scores represent more anxiety.

    Time frame: 4-weeks post-randomization

Secondary outcomes

  1. Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0

    The PROMIS Anxiety 4a v1.0 is a 4 item scale that asks participants, in the past 7 days, how often: (1) "I felt fearful"; (2) "I found it hard to focus on anything other than my anxiety"; (3) "My worries overwhelmed me"; and (4) "I felt uneasy". Items are scored on a 5-point scale (range 1-5), and response options include "never", "rarely", "sometimes", "often", and "always". Raw scores are converted into T scores standardised in the US adult general population (mean=50, standard deviation=10). Higher scores represent more anxiety.

    Time frame: 10-weeks post-randomization

  2. Depression Symptoms: Patient Health Questionnaire (PHQ-8)

    PHQ-8 items measure depressive symptoms over the last 2 weeks on a 4-point scale, ranging from 0 (not at all) to 3 (nearly every day) with higher scores (range 0 to 24) indicating more depressive symptoms. The PHQ-8 performs equivalently to the PHQ-9, which has been shown to be a valid measure of depressive symptoms in patients with scleroderma.

    Time frame: 4-weeks post-randomization, 10-weeks post-randomization

  3. Loneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6)

    The 6-item ULS-6 is a short version of the 20-item ULS, which is designed to assess subjective feelings of loneliness and social isolation. Respondents indicate the degree to which feelings described in each item apply to them. Items are scored on a 4-point scale from 0 (never) to 3 (often); total scores range from 0 to 18 with higher scores indicating greater loneliness.

    Time frame: 4-weeks post-randomization, 10-weeks post-randomization

  4. Boredom: Multidimensional State Boredom Scale (MSBS-8)

    The full MSBS is a 29-item measure of state boredom with items on five factors that load onto a single higher-order factor. The 8-item MSBS is a short version with scores that correlate very closely to scores from the full MSBS (r = 0.96) Item responses are on a 7-point Likert-type scale from 1 (strongly disagree) to 7 (strongly agree) and assess the degree to which each item reflects the respondant's experience currently. Total scores range from 8 to 56 with higher scores reflecting greater boredom.

    Time frame: 4-weeks post-randomization, 10-weeks post-randomization

  5. Physical Activity: International Physical Activity Questionnaire - Modified for the Elderly (IPAQ-E)

    The 4-item IPAQ-E is a short-form version of the full IPAQ designed to assess physical activity over the last week, including time spent sitting, walking, and in moderate and vigorous physical activity. Compared to other short-form versions of the IPAQ, the IPAQ-E has examples of exercise specific to older adults. The unit of measure is MET(metabolic equivalent turnover)-minutes per week, which larger values meaning greater activity.

    Time frame: 4-weeks post-randomization, 10-weeks post-randomization

  6. Adverse Effects

    Adverse Effects will be assessed by ongoing monitoring during the trial and by asking participants post-intervention to describe any adverse experiences or outcomes that may have occurred.

    Time frame: 4-weeks post-randomization, 10-weeks post-randomization

  7. Fear: COVID-19 Fears Questionnaire for Chronic Medical Conditions

    The COVID-19 Fears Questionnaire for Chronic Medical Conditions is a 10-item scale that ask participants to rate, on a typical day in the last week, how much they were afraid from "not at all" to "extremely" about aspects of COVID-19. Items are scored on a 5-point scale (range 1-5), total scores range from 10 to 50. Higher scores represent greater fear. The scale has been validated among people with scleroderma.

    Time frame: 4-weeks post-randomization, 10-weeks post-randomization

07

Results

Posted Feb 1, 2023

Participant flow

From April 9, 2020 to April 27, 2020, we recruited participants into a new SPIN COVID-19 Cohort internationally via social media announcements and from an existing systemic sclerosis cohort (the SPIN cohort). Ongoing SPIN Cohort participants were invited to enrol by email and via notices during regular SPIN Cohort assessments. Recruitment announcements were posted via social media and through patient organisation partners.

Participant flow — Overall Study
MilestoneSPIN-CHAT: Videoconference InterventionWait-list Control
Started8686
Completed measures post-intervention7883
Completed7576
Not completed1110

Outcome measures

PrimaryAnxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0

The PROMIS Anxiety 4a v1.0 is a 4 item scale that asks participants, in the past 7 days, how often: (1) "I felt fearful"; (2) "I found it hard to focus on anything other than my anxiety"; (3) "My worries overwhelmed me"; and (4) "I felt uneasy". Items are scored on a 5-point scale (range 1-5), and response options include "never", "rarely", "sometimes", "often", and "always". Raw scores are converted into T scores standardised in the US adult general population (mean=50, standard deviation=10). Higher scores represent more anxiety.

Time frame:
4-weeks post-randomization
Reported as:
Mean · T-score
Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0
T-scoreSPIN-CHAT: Videoconference InterventionWait-list Control
Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.056.9 ± 7.658.8 ± 6.3
SecondaryAnxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0

The PROMIS Anxiety 4a v1.0 is a 4 item scale that asks participants, in the past 7 days, how often: (1) "I felt fearful"; (2) "I found it hard to focus on anything other than my anxiety"; (3) "My worries overwhelmed me"; and (4) "I felt uneasy". Items are scored on a 5-point scale (range 1-5), and response options include "never", "rarely", "sometimes", "often", and "always". Raw scores are converted into T scores standardised in the US adult general population (mean=50, standard deviation=10). Higher scores represent more anxiety.

Time frame:
10-weeks post-randomization
Reported as:
Mean · T-score
Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0
T-scoreSPIN-CHAT: Videoconference InterventionWait-list Control
Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.055.1 ± 6.758.2 ± 8.2
SecondaryDepression Symptoms: Patient Health Questionnaire (PHQ-8)

PHQ-8 items measure depressive symptoms over the last 2 weeks on a 4-point scale, ranging from 0 (not at all) to 3 (nearly every day) with higher scores (range 0 to 24) indicating more depressive symptoms. The PHQ-8 performs equivalently to the PHQ-9, which has been shown to be a valid measure of depressive symptoms in patients with scleroderma.

Time frame:
4-weeks post-randomization, 10-weeks post-randomization
Reported as:
Mean · score on a scale
Depression Symptoms: Patient Health Questionnaire (PHQ-8)
score on a scaleSPIN-CHAT: Videoconference InterventionWait-list Control
4-weeks post-randomization6.6 ± 4.66.9 ± 5.4
10-weeks post-randomization5.5 ± 4.27.3 ± 5.9
SecondaryLoneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6)

The 6-item ULS-6 is a short version of the 20-item ULS, which is designed to assess subjective feelings of loneliness and social isolation. Respondents indicate the degree to which feelings described in each item apply to them. Items are scored on a 4-point scale from 0 (never) to 3 (often); total scores range from 0 to 18 with higher scores indicating greater loneliness.

Time frame:
4-weeks post-randomization, 10-weeks post-randomization
Reported as:
Mean · score on a scale
Loneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6)
score on a scaleSPIN-CHAT: Videoconference InterventionWait-list Control
4-weeks post-randomization8.6 ± 3.79.5 ± 3.6
10-weeks post-randomization8.6 ± 3.49.4 ± 3.8
SecondaryBoredom: Multidimensional State Boredom Scale (MSBS-8)

The full MSBS is a 29-item measure of state boredom with items on five factors that load onto a single higher-order factor. The 8-item MSBS is a short version with scores that correlate very closely to scores from the full MSBS (r = 0.96) Item responses are on a 7-point Likert-type scale from 1 (strongly disagree) to 7 (strongly agree) and assess the degree to which each item reflects the respondant's experience currently. Total scores range from 8 to 56 with higher scores reflecting greater boredom.

Time frame:
4-weeks post-randomization, 10-weeks post-randomization
Reported as:
Mean · score on a scale
Boredom: Multidimensional State Boredom Scale (MSBS-8)
score on a scaleSPIN-CHAT: Videoconference InterventionWait-list Control
4-weeks post-randomization28.6 ± 10.631.1 ± 10.8
10-weeks post-randomization26.7 ± 10.829.3 ± 11.2
SecondaryPhysical Activity: International Physical Activity Questionnaire - Modified for the Elderly (IPAQ-E)

The 4-item IPAQ-E is a short-form version of the full IPAQ designed to assess physical activity over the last week, including time spent sitting, walking, and in moderate and vigorous physical activity. Compared to other short-form versions of the IPAQ, the IPAQ-E has examples of exercise specific to older adults. The unit of measure is MET(metabolic equivalent turnover)-minutes per week, which larger values meaning greater activity.

Time frame:
4-weeks post-randomization, 10-weeks post-randomization
Reported as:
Mean · MET-minutes per week
Physical Activity: International Physical Activity Questionnaire - Modified for the Elderly (IPAQ-E)
MET-minutes per weekSPIN-CHAT: Videoconference InterventionWait-list Control
4-weeks post-randomization2984 ± 27342769 ± 3198
10-weeks post-randomization2737 ± 22553171 ± 3475
SecondaryAdverse Effects

Adverse Effects will be assessed by ongoing monitoring during the trial and by asking participants post-intervention to describe any adverse experiences or outcomes that may have occurred.

Time frame:
4-weeks post-randomization, 10-weeks post-randomization
Reported as:
Number · adverse events
Adverse Effects
adverse eventsSPIN-CHAT: Videoconference InterventionWait-list Control
4-weeks post-randomization00
10-weeks post-randomization00
SecondaryFear: COVID-19 Fears Questionnaire for Chronic Medical Conditions

The COVID-19 Fears Questionnaire for Chronic Medical Conditions is a 10-item scale that ask participants to rate, on a typical day in the last week, how much they were afraid from "not at all" to "extremely" about aspects of COVID-19. Items are scored on a 5-point scale (range 1-5), total scores range from 10 to 50. Higher scores represent greater fear. The scale has been validated among people with scleroderma.

Time frame:
4-weeks post-randomization, 10-weeks post-randomization
Reported as:
Mean · score on a scale
Fear: COVID-19 Fears Questionnaire for Chronic Medical Conditions
score on a scaleSPIN-CHAT: Videoconference InterventionWait-list Control
4-weeks post-randomization26.3 ± 9.428.7 ± 10.3
10-weeks post-randomization25.4 ± 10.627.1 ± 10.7

Adverse events

Collected over Assessed throughout the intervention period (i.e. 4-weeks post-randomization), and during the post-trial assessment period (i.e. 10-weeks post-randomization).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPIN-CHAT: Videoconference Intervention0/86 (0%)0/86 (0%)0/86 (0%)
Wait-list Control0/86 (0%)0/86 (0%)0/86 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)SPIN-CHAT: Videoconference InterventionWait-list ControlTotal
Mean56.0 ± 11.954.0 ± 10.955.0 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)SPIN-CHAT: Videoconference InterventionWait-list ControlTotal
Female8181162
Male5510
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SPIN-CHAT: Videoconference InterventionWait-list ControlTotal
White7363136
Black4812
Other91524
Region of Enrollment
Region of Enrollment(Participants)SPIN-CHAT: Videoconference InterventionWait-list ControlTotal
Canada272350
United States273461
France151429
United Kingdom7512
Australia6511
Germany022
India011
Netherlands101
New Zealand101
Nicaragua011
Norway011
Philippines202
Education
Education(years)SPIN-CHAT: Videoconference InterventionWait-list ControlTotal
Mean15.4 ± 3.416.4 ± 3.315.9 ± 3.4
Married or living as married
Married or living as married(Participants)SPIN-CHAT: Videoconference InterventionWait-list ControlTotal
Count of participants5351104
Living alone
Living alone(Participants)SPIN-CHAT: Videoconference InterventionWait-list ControlTotal
Count of participants132134
Working part-time or full-time
Working part-time or full-time(Participants)SPIN-CHAT: Videoconference InterventionWait-list ControlTotal
Count of participants372966

8 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Sir Mortimer B. Davis Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
09

References and documents

Publications

  • Thombs BD, Kwakkenbos L, Levis B, Bourgeault A, Henry RS, Levis AW, Harb S, Tao L, Carrier ME, Bustamante L, Duchek D, Dyas L, El-Baalbaki G, Ellis K, Rice DB, Wurz A, Nordlund J, Gagarine M, Turner KA, Ostbo N, Culos-Reed N, Hebblethwaite S, Patten S, Bartlett SJ, Varga J, Mouthon L, Markham S, Martin MS, Benedetti A; SPIN-CHAT Patient Advisory Team and Program Facilitators; Scleroderma Patient-centered Intervention Network Investigators. Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial. Lancet Rheumatol. 2021 Jun;3(6):e427-e437. doi: 10.1016/S2665-9913(21)00060-6. Epub 2021 Apr 16. PubMed 33899008 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Upon request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 12 months after the collection of the primary outcome

Access criteria: Approval of proposed purpose for data access

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Jun 2020, 1 month.

Results were first posted in Feb 2023, 2 years 7 months after primary completion.

Of 51 non-industry interventional studies with no phase under Scleroderma, Diffuse, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's 1 month is below that.

Counting every sponsor, half of 53 studies reached it within 16 months; a quarter within 4 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2020
First posted
Apr 6, 2020
StartActual
Apr 9, 2020
Primary completionActual
Jun 3, 2020
CompletionActual
Jul 24, 2020
Results first posted
Feb 1, 2023
Last update
Feb 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04335279
Lead sponsor
Lady Davis Institute
Responsible party
Brett D Thombs (Senior Investigator, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital; Professor, Faculty of Medicine, McGill University, Sir Mortimer B. Davis - Jewish General Hospital) — Principal investigator
First posted
Apr 6, 2020
Start date
Apr 9, 2020
Primary completion
Jun 3, 2020
Completion
Jul 24, 2020
Results posted
Feb 1, 2023
Last update
Feb 1, 2023

Study contacts

Brett D Thombs, PhD
principal investigator · Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital, McGill University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion